Present esent st status us of of the he RCN CNP cycl - - PowerPoint PPT Presentation

The he 9th 9th Jap apan- China na Joint nt Nucle lear ar Physics Sympo posium JCNP 201 2015

Present esent st status us of

• f

the he RCN CNP cycl cyclotron facility ty and nd fut utur ure e pr prospec spects s of

• f

cyclot

• tron

ron appl pplications

• ns

Research Center for Nuclear Physics(RCNP), Research Center for Nuclear Physics(RCNP), Osaka University Osaka University

Mits itsuhir uhiro F

• FUKUD

UKUDA

November 10, 2015

*

• 11 staffs
• K. Hatanaka, M. Fukuda, T. Yorita, H. Ueda,
• Y. Yasuda, T. Saito, K. Shimada,
• S. Morinobu, K. Nagayama, H. Tamura
• 3 students
• K. Kamakura, T. Kume, S. Hara
• 9 operators (SHI Accelerator Service Ltd.)

*

• 1. Overview of the RCNP cyclotron

facility

• 2. Upgrade of the cyclotrons and

beam lines

• 3. Applications to Medicine
• 4. Summary

１．Overview ew of

• f the

e RCNP RCNP cyclot lotron facili lity

Rese esearch arch Ce Center nter fo for Nu r Nucle clear P ar Phys hysics ics

Ring Cyclo lotron B Build ldin ing AVF C Cyclo lotron B Build lding Main B Bui uilding Ra Radio I Isot sotope B Buil ildin ing

• 1971

971 Foun

• undat

dation ion of

• f RC

RCNP NP

• 1973

973 Comp

• mplet

letion ion of

• f th

the A e AVF VF cyc cyclot lotron ron fa facil cility ity（42 y 2 year ears o s old ld）

• 1976

976 Expe xperim riment ents s s star tarted ted.

• 1991

991 Comp

• mplet

letion ion of

• f th

the R e Ring ing cy cyclo clotro tron f n faci acilit lity

RC RCNP Cyclotron F n Facility

K=400 MeV, Since 1992 Ring Cyclotron AVF Cyclotron K=140 MeV, Since 1973 Grand Raiden Precise physics MuSIC IC Muon science Ultra cold neutron Fundamental science

RI Be Beam

Unstable nucleus

Qua uasi si-mon

• no
• en

ener erge geti tic c neu eutr tron

• n

Nuclear data White neutron irradiation Semiconductor

Akira SATO MuSIC

7

New CW muon beam line for MuSIC at RCNP

Muon beam characteristics

Positive muon：DC-μSR beam size：φ10mm angle：< 50mrad intensity：2~4 x 104/sec

• Negative muon：nuclear phys. chemi. μ-X
• beam size：φ10mm~Φ50mm
• angle：< 200mrad
• intensity：2x104 ~2x105/sec

*

FC FC

HIPIS

TQ1 TQ2 WIEN F.

Typical transmission through AVF cyclotron is 5 - 7 %. 90 % emittance: εx = 6π mm・mrad、 εy = 10π mm・mrad

BM2 GL2 BM3 BM1

TQ1 TQ2

GL1 TMP

S C-ECR

18GHz S C-ECR for heavy ions NEOMAFIOS for p, d, He, Li ~ Mg, Ar 2.45GHz HIPECR for intense p HIPIS for polarized p, d

HIPECR NEOMAFIOS

Axial Injection to AVF cyclotron

*

1973 Completed 1991 Mainly used as an injector of the ring cyclotron Proton 10～80MeV

【Specifications】 ・Energy of ions with M/Q≦5 proton ≦ 80 MeV D+, 4He2+ ≦ 35 MeV/n

3He2+

≦ 180 MeV Heavy Ion ≦ 140×(Q/A)2 ・RF 6～19 MHz ・Acc. harmonics 1, 3 ・Average field ≦ 1.7 T

*

1991 Completed

Proton 100～420MeV

Bypass beam line

【Specifications】 ・Energy Designed for light ions with M/Q≦3 proton ≦ 420 MeV D+, 4He2+ ≦ 100 MeV/n

3He2+

≦ 170 MeV/n Heavy Ion ≦ 400×(Q/A)2 ・RF 30～52 MHz ・Acc. harmonics 6, 10, 12, 18 ・Average field 8 kG(max.17.5)

0h 1200h 2400h 3600h 4800h 6000h 7200h

*Annua

nnual O Opera peration T Tim ime f e fro rom 1 1977 977 to 201 2014

Beam Time (hours) K140 AVF cyclotron K400 Ring cyclotron Cyclotron upgrade

5000～6000 hours/year

Proton 2479h Deuteron 294h 4He 500h 12C 745h 13C 314h 18O 262h 22Ne 231h 24Mg 277h Pol.-P 63h Pol.-D 69h

*Cyclotron O

ron Oper peration D

• n Data i

in n JF JFY201 2014

Total ： 5239 hours

（Experiments, beam tuning,

beam developments）

・p, d, 3He, 4He ： 3408 h ・Heavy ions（≧12C） ： 1830 h

２．Up Upgr grade of f the he cyclotrons ns and d bea eam m line nes

* Updat

ate program am of Cyc yclotron Fac acil ilit ity in in JFY2 FY2013

Control system ・Upgrade of OS and interlock system LEBT system ・New buncher ・Additional glazer lens AVF cyclotron resonator ・Replacement of the connection part between a Dee electrode and a cavity Ring cyclotron ・Modification of a fine tuning system

• f the flattop cavity

・Renewal of electrostatic and magnetic channels for injection and extraction: EIC, EEC, MIC, MEC ・ New high-temperature superconducting switching magnet MuSIC ・Muon beam line Grand-RAIDEN ・New forward beam line

*

・PC&OS u update： Wi Windo dowsXP → Windows7 32bit ・Man-machine I Interface: u upgrade t to

• Ｉｎｔｏｕｃｈ ７(v.9.010.1)

・Console display： wide display ・Interlock system： PLCs were partially adopted.

New buncher and solenoid lens

Present buncher of harmonic voltage combination type(1f+2f+3f) New buncher of charge/discharge type for heavy ion injection

Vmax: 1200V@2MHz 750V@6MHz 200V@20MHz

New solenoid lens Present glazer lens

・2008 Leak repairing for 4 lines by Cu wire & solder ・2009, 2010 leak again at the two repaired pipes

Transition part of the AVF cyclotron resonator

Fine tuning of the ring cyclotron flattop cavity

Coarse tuner (Shorting Plate) + Fine tune mode ※2 Former fine tuner (Compensator) 200mm extention ※1

ΔEZ(M (Max)/ )/Δf100 00kH kHz Δf/mm Po Pos.

• s. Res
• Reso. At 1

150 M 50 MHz Shorting Plate 0. 0.32% 32% 323kHz 0.5μm Compensator 2. 2.30% 30% 0.4kHz 300μm ※1 ※2

Enlargement of baffle slit aperture to improve beam transmission

date ion BS_ACC1 (nA) BS_INJ (nA) BS_10C (nA) 2010/10/4 22Ne 1760MeV 680 1050 1860 2010/11/18 18O 1080MeV 360 1000 1900 2011/12/29 18O 1080MeV 570 910 1700 2013/5/19 36Ar 1872MeV 182 384 718 2013/7/4 16O 1280MeV 1000 2500 4500 2013/10/11 16O 1280MeV 200 800 1500 2014/6/12 13C 780MeV 1200 1450 2700 2014/6/28 22Ne 1760MeV 800 1200 2200 2014/11/4 12C 600MeV 54 60 160 2015/4/30 18O 1080MeV 1580 1800 4400 2015/5/24 40Ar 2060MeV 250 330 1200 2015/6/15 13C 780MeV 29 30 95

Mod. Mod.

Injection efficiency

Mod.

BS_10C: located ~20m upstream of BS_INJ BS_INJ MIC 15x15  33x30

High Temp. Superconducting Switching magnet SW1

SW1

Pulse mode operation: Lumping speed < ± 20 A/s Typical sequence: 0A - (10s)  200 A - (100s)  200 A - (10s)  0 A (300s)

For parallel experiments by time-sharing for UCN and MuSIC

SC Wire: Sumitomo Electric Industry, DI-BSCCO TYPE Hti-CA50 4.6±0.3mmW x 0.41±0.04t, Ic @ 77 K, self field≧180 A

３．Appli plication

• ns to

to Medic icin ine

Cons nstruc uction o

• f bea

eam l line ines f for r med edical us use

AVF cyclotron

K-cour urse se

K-cour course in the S se in the S-exp. room

• xp. room

Ｍ-exp. Room

F-course course

F-cour course in the M e se in the M exp. room

• xp. room

0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 2006 2007 2008 2009 2010 2011 2012 2013 2014

Ratio of the RI production beam time to the all beam time (％）

341h ４０９h ２８３h 93h １36h

Japanese Fiscal Year

187h 238h 223h １47h

※Regular beam time Several days／month （～4.4％ of total beam time）

Annual beam time for RI production

・targeting the tumor from outside by suppressing the damage to normal tissues ・effective to the cancer that other radiation is useless

Difference between the heavy particle therapy and the targeted alpha therapy

Conventional heavy particle therapy: External irradiation of heavy particles from an accelerator

Accel. facility Accel.

Patients move to the facility RI will be delivered to hospitals

Treatment at accelerator facility Treatment at a hospital

Targeted alpha therapy: Administration of molecules labelled by alpha-emitting-RI and pinpoint irradiation of a cancer cell from inside.

・Attacking only to cancer cells by highly efficient targeting ・smaller invasion to surrounding organ due to short range ・effective to the advanced cancer like remote change cancer

Application of targeted alpha therapy to the advanced cancer

Ratio of cancer type at the 1st medical examination

Primary organ localization Belonging lymph node change Next organ permeating Remote change

47% 22% 12% 19%

・Removal by surgery ・Radiation therapy ・Chemotherapy ・Immunity method

• f treatment

・Chemotherapy ・Immunity method

• f treatment

5-years relative survival rate

74.5% 47.2% 17.9% 6.1% Application of the targeted alpha therapy

1/3 of cancer patients has advanced cancer at the 1st medical examination.

Very low survival rate 大阪府におけるがん登録年報 第６７報 （大阪府健康福祉部、大阪府医師会、大阪府成人病センター）

・Practically used targeted beta-ray therapy

Targeted Alpha-ray Therapy

⇒

antigen

・Utilization of targeting molecule like antibody ・Pinpoint radiation irradiation and cell-death leading ⇒ no side effect and maximization of treatment effect

・ゼヴァリン（90Y-抗CD20抗体）：B細胞性非ホジキンリンパ腫 ・ベキサール（131I-抗CD20抗体）：B細胞性非ホジキンリンパ腫 ・177Lu-DOTA-[Tyr3]-octreotide（ソマトスタチンアナログ）：神経内分泌腫瘍 Short range, high LET, short half life ⇒ decrease of side effect, enhanced effect Issues： not so effective for a solid cancer, side effect caused by radiation exposure to normal tissues around the tumor β-ray utilization α−ray ・targeted β-ray therapy ・targeted α-ray therapy

Alpha pha-emi mitter r sui uitable for r targ rget eted ed thera herapy

Collaboration for realizing the targeted alpha therapy at Osaka University

Production

• Large amount of

RI production

Separation

• Automatic

separation system

Labeling/Synthesis

• High efficient targeting

at tumor

Clinic

• Treatment by the targeted

alpha therapy Graduate Schools of Science,

Department of Chemistry and Macromolecular Science,

Radioisotope Research Center RCNP

Graduate Schools of Science, Department of Physics

Targeted alpha therapy Skeleton cyclotron Radioactive materials synthesis technology Radio nucleus separation technology Certification facility for radioactive medicine

Imaging

Advanced cancer

Graduate Schools of Medicine

４．Summary

• Status of the RCNP cyclotron facility

・Partially updated in 2013 and 2014 ・Significantly deteriorated, but still works so-so ・Severe issue : budget for electricity

• Attractive prospects of cyclotron applications

・New beam line was installed to produce radio- isotopes for medical use. ・New project for realization of the targeted alpha- ray therapy has started by steady cooperation among Graduate School of Medicine, Graduate School of Science and RCNP.